Drug Intake and Actinic Keratosis: A Case-Control Study
Keywords:
drug reaction, photosensitivity, actinic keratosis, angiotensin receptor blockers, antiplatelet drugAbstract
Background: Actinic keratosis (AK) is a form of premalignant keratinocyte dysplasia. Recently, the role of photosensitizing drugs in the development of AK has been postulated.
Objective: This study evaluated a possible association between the use of photosensitizing drugs and the development of AK. A secondary aim was to identify a possible association between any medication other than those primarily examined and AK.
Methods: A single-center, case-control study assessed the cumulative drug exposure of 90 patients with AK and 90 controls visiting a dermatology service for other skin ailments. Before the visit, patients were interviewed to collect data on daily therapy and the lag-time of discontinued drugs within the last 2 years, and to record the drug’s active ingredient, dosage, and duration of therapy. In addition, sociodemographic characteristics including age, sex, educational level, skin phototype, and cumulative sun exposure habits were gathered.
Results: By logistic regression, exposures to angiotensin II receptor blockers (ARBs) and antiplatelet agents were identified as independent risk factors for the development of AK. ARB intake was associated with AK only at high exposure (OR = 13.6; 95% CI, 2.0-93.8). The use of antiplatelet drugs was borderline, yet not significant, at low exposure (OR = 3.31; 95% CI, 0.86-12.7), but increased in a dose-dependent manner. The strongest correlation was found at the highest cumulative dose (>1100 dose unit-years (OR = 4.38; 95% CI, 1.16-16.6).
Conclusions: High exposure to ARBs and antiplatelet agents may promote AK carcinogenesis in at-risk patients.
References
Criscione VD, Weinstock MA, Naylor MF, et al; Department of Veteran Affairs Topical Tretinoin Chemoprevention Trial Group. Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer. 2009;115(11):2523. DOI: 10.1002/cncr.24284. PMID: 19382202.
Siegel JA, Korgavkar K, Weinstock MA. Current perspective on actinic keratosis: a review. Br J Dermatol. 2017;177(2):350-358. DOI: 10.1111/bjd.14852. PMID: 27500794.
Quaedvlieg PJ, Tirsi E, Thissen MR, et al. Actinic keratosis: how to differentiate the good from the bad ones? Eur J Dermatol. 2006;16(4):335-339. PMID: 16935787.
Hensen P, Müller ML, Haschemi R, et al. Predisposing factors of actinic keratosis in a North-West German population. Eur J Dermatol. 2009;19(4):345. DOI: 10.1684/ejd.2009.0706. PMID: 19470418.
Frost CA, Green AC, Williams GM. The prevalence and determinants of solar keratoses at a subtropical latitude (Queensland, Australia). Br J Dermatol. 1998;139(6):1033-1039. DOI: 10.1046/j.1365-2133.1998.02560.x. PMID: 9990367.
de Berker D, McGregor JM, Mohd Mustapa MF, Exton LS, Hughes BR. British Association of Dermatologists' guidelines for the care of patients with actinic keratosis 2017. Br J Dermatol 2017;176(1):20-43. DOI: 10.1111/bjd.15107. PMID: 28098380.
Placzek M, Eberlein-König B, Przybilla B. Association between actinic keratoses and potentially photosensitizing drugs. N Engl J Med 1999;341(19):1474-1475. DOI: 10.1056/NEJM199911043411915. PMID: 10577103.
European Medicines Agency-Pharmacovigilance Risk Assessment Committee (PRAC). PRAC recommendations on signals. 1 October 2018. Accessed: February 14, 2021. Available at: https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-3-6-september-2018-prac-meeting_en-0.pdf.
Pedersen SA, Gaist D, Schmidt SAJ, Hölmich LR, Friis S, Pottegård A. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark. J Am Acad Dermatol 2018;78(4):673-681.e9. DOI: 10.1016/j.jaad.2017.11.042. PMID: 29217346.
Pottegård A, Hallas J, Olesen M, et al. Hydrochlorothiazide use is strongly associated with risk of lip cancer. J Intern Med 2017;282(4):322-331. DOI: 10.1111/joim.12629. PMID: 28480532.
Friedman GD, Asgari MM, Warton EM, Chan J, Habel LA. Antihypertensive drugs and lip cancer in non-Hispanic whites. Arch Intern Med. 2012;172(16):1246-1251. DOI: 10.1001/archinternmed.2012.2754. PMID: 22869299.
O'Gorman SM, Murphy GM. Photosensitizing medications and photocarcinogenesis. Photodermatol Photoimmunol Photomed. 2014;30(1):8-14. DOI: 10.1111/phpp.12085. PMID: 24393207.
Jensen AØ, Thomsen HF, Engebjerg MC, Olesen AB, Sørensen
HT, Karagas MR. Use of photosensitising diuretics and risk of skin cancer: a population-based case-control study. Br J Cancer. 2008;99(9):1522-1528. DOI: 10.1038/sj.bjc.6604686. PMID: 18813314.
Schmidt SAJ, Schmidt M, Mehnert F, et al. Use of antihypertensive drugs and risk of skin cancer. J Eur Acad Dermatol Venereol. 2015;29(8):1545-1554. DOI: 10.1111/jdv.12921. PMID: 25640031.
Pottegård A, Pedersen SA, Schmidt SAJ, et al. Use of hydrochlorothiazide and risk of skin cancer: a nationwide Taiwanese case-control study. Br J Cancer. 2019;121(11):973-978. DOI: 10.1038/s41416-019-0613-4. PMID: 31673105.
Han S, Wolfe CM, Angnardo L, et al. Hydrochlorothiazide use and increased squamous cell carcinoma burden in a high-risk Mohs population: a cross-sectional study. Dermatol Surg. 2020;46(5):704-708. DOI: 10.1097/DSS.0000000000001875.
Park E, Lee Y, Jue MS. Hydrochlorothiazide use and the risk of skin cancer in patients with hypertensive disorder: a nationwide retrospective cohort study from Korea. Korean J Intern Med. 2019;35(4):917-928. DOI: 10.3904/kjim.2019.218.
Olde Engberink RHG, van der Hoeven NV, Zwinderman AH, van den Born BH. Hydrochloorthiazide en huidkanker [Hydrochlorothiazide and skin cancer]. Ned Tijdschr Geneeskd. 2019;163:D3755.
MHRA drug safety update: hydrochlorothiazide and non-melanoma skin cancer. Drug Ther Bull. 2019;57(5):70. DOI: 10.1136/dtb.2019.000023. PMID: 31018928.
Morales DR, Pacurariu A, Slattery J, Kurz X. Association between hydrochlorothiazide exposure and different incident skin, lip and oral cavity cancers: A series of population-based nested case-control studies. Br J Clin Pharmacol. 2020; 86(7):1336-1345. DOI: 10.1111/bcp.14245. PMID: 32068906.
Kreutz R, Algharably EAH, Douros A. Reviewing the effects of thiazide and thiazide-like diuretics as photosensitizing drugs on the risk of skin cancer. J Hypertens. 2019;37(10):1950-1958. DOI: 10.1097/HJH.0000000000002136. PMID: 31145177.
Becquart O, Guillot B, Bourrain J-L, Duflos C, Du-Thanh A. Risque de cancers cutanés sous hydrochlorothiazide: revue systématique [Hydrochlorothiazide use and risk of skin cancers: A systematic review]. Rev Med Interne. 2019;40(9):617-622. DOI: 10.1016/j.revmed.2019.04.008. PMID: 31101331.
Shin D, Lee ES, Kim J, Guerra L, Naik D, Prida X. Association between the use of thiazide diuretics and the risk of skin cancers: a meta-analysis of observational studies. J Clin Med Res. 2019;11(4):247-255. DOI: 10.14740/jocmr3744. PMID: 30937114.
Faconti L, Ferro A, Webb AJ, Cruickshank JK, Chowienczyk PJ; British and Irish Hypertension Society. Hydrochlorothiazide and the risk of skin cancer. A scientific statement of the British and Irish Hypertension Society. J Hum Hypertens. 2019;33(4):257-258. DOI: 10.1038/s41371-019-0190-2. PMID: 30842544.
Viola E, Coggiola Pittoni A, Drahos A, Moretti U, Conforti A. photosensitivity with angiotensin ii receptor blockers: a retrospective study using data from VigiBase®. Drug Saf. 2015;38 (10):889-894. DOI: 10.1007/s40264-015-0323-7. PMID: 26187686.
Nardone B, Orrell KA, Vakharia PP, West DP. Skin cancer associated with commonly prescribed drugs: tumor necrosis factor alpha inhibitors (TNF-αIs), angiotensin-receptor blockers (ARBs), phosphodiesterase type 5 inhibitors (PDE5Is) and statins—weighing the evidence. Expert Opin Drug Saf. 2018;17(2):139-147. DOI: 10.1080/14740338.2018.1400530. PMID: 29103328.
Nardone B, Majewski S, Kim AS, et al. Melanoma and non-melanoma skin cancer associated with angiotensin-converting-enzyme inhibitors, angiotensin-receptor blockers and thiazides: a matched cohort study. Drug Saf. 2017;40(3):249-255. DOI: 10.1007/s40264-016-0487-9. PMID: 27943160.
Moscarelli L, Zanazzi M, Mancini G, et al. Keratinocyte cancer prevention with ACE inhibitors, angiotensin receptor blockers or their combination in renal transplant recipients. Clin Nephrol. 2010;73:439-445. DOI: 10.5414/CNP73439. PMID: 20497756
Christian JB, Lapane KL, Hume AL, Eaton CB, Weinstock MA; VATTC Trial. Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial. J Natl Cancer Inst. 2008;100:1223-1232. DOI: 10.1093/jnci/djn262. PMID: 18728281
Schmitt J, Miot H. Oral acetylsalicylic acid and prevalence of actinic keratosis. Rev Assoc Médica Bras. 2014;60(2):131-138. DOI: 10.1590/1806-9282.60.02.010. PMID: 24919000.
Published
Issue
Section
License
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
How to Cite
Share
